25-OH Vitamin D Longevity-Medicine Target Ranges

What does the 25-OH vitamin D test measure?

Serum 25-hydroxyvitamin D, written 25(OH)D, is the blood marker used to judge vitamin D status. The ergocalciferol label describes the first hydroxylation of ergocalciferol in the liver (to 25-hydroxyvitamin D) and the second in the kidneys (to 1,25-dihydroxyvitamin D) [6]. Results are reported in ng/mL or nmol/L, and 1 ng/mL equals 2.5 nmol/L, so 20 ng/mL is 50 nmol/L [1].

Does any guideline actually set a longevity target?

The 2024 Endocrine Society guideline states there is no clear evidence defining an optimal 25(OH)D for disease prevention, and it states that the society no longer endorses the 2011 target of 30 ng/mL (75 nmol/L) or specific levels used to define sufficiency, insufficiency and deficiency [3][7].

The Institute of Medicine report behind the dietary reference intakes gave population requirement levels. In that 2011 report, 16 ng/mL (40 nmol/L) covers the requirement of about half the population and 20 ng/mL (50 nmol/L) covers at least 97.5%, matching the recommended dietary allowance [2][1]. The same report said levels above 30 ng/mL (75 nmol/L) are not consistently associated with more benefit, and that levels above 50 ng/mL (125 nmol/L) should raise concern about potential adverse effects [2]. The US Preventive Services Task Force noted in 2021 that no single serum cut-point defines deficiency [8].

Where might the 40 to 60 ng/mL figure come from?

A 2014 BMJ analysis by Schöttker and colleagues linked lower 25(OH)D with higher mortality, but it did not identify 40 to 60 ng/mL as a target [9]. It pooled individual participant data from 8 prospective cohort studies in Europe and the US, covering 26,018 men and women aged 50 to 79 [9]. Comparing the bottom with the top quintile of 25(OH)D gave a pooled risk ratio of 1.57 (95% CI 1.36 to 1.81) for all-cause mortality, with curvilinear, inverse dose-response curves across quintiles [9]. A cancer mortality association appeared only in people with a history of cancer (risk ratio 1.70, 95% CI 1.00 to 2.88) [9].

The quintiles used cohort-specific and subgroup-specific cut-off values, so the 1.57 figure is a bottom-versus-top comparison, not a comparison of levels below 20 ng/mL against a 40 to 50 ng/mL range [9]. The authors concluded that results from a long-term randomized trial addressing longevity were awaited before vitamin D supplementation could be recommended in most individuals with low 25(OH)D levels [9]. Observational associations of this kind cannot show that raising a person's level changes their outcome.

What the large randomized trials found

VITAL randomized 25,871 US adults (men 50 and older, women 55 and older, including 5,106 Black participants) to vitamin D3 2,000 IU/day or placebo, with a median follow-up of 5.3 years [10]. Invasive cancer was diagnosed in 793 participants on vitamin D and 824 on placebo (HR 0.96, 95% CI 0.88 to 1.06). Major cardiovascular events occurred in 396 and 409 respectively (HR 0.97, 95% CI 0.85 to 1.12). Neither primary endpoint was reduced [10].

The fracture analysis of the same cohort confirmed 1,991 fractures in 1,551 participants over the same median follow-up [11]. Total fractures: HR 0.98 (95% CI 0.89 to 1.08); nonvertebral: HR 0.97 (0.87 to 1.07); hip: HR 1.01 (0.70 to 1.47). Participants were not recruited on the basis of vitamin D deficiency, low bone mass or osteoporosis [11].

A meta-analysis of individual participant data did find an effect that depended on baseline level. In 25 randomized trials with 11,321 participants, vitamin D reduced acute respiratory tract infection risk overall (adjusted odds ratio 0.88, 95% CI 0.81 to 0.96). The protective effect was seen with daily or weekly dosing without boluses (0.81, 0.72 to 0.91) but not with one or more bolus doses (0.97, 0.86 to 1.10). Among those on daily or weekly dosing, it was stronger with baseline 25(OH)D below 25 nmol/L (0.30, 0.17 to 0.53) than at or above 25 nmol/L (0.75, 0.60 to 0.95) [12].

Two older meta-analyses of trials in older adults found benefit that VITAL did not show for fractures. Vitamin D at 700 to 800 IU/day reduced hip fracture risk by 26% (pooled RR 0.74, 95% CI 0.61 to 0.88; 3 trials, 5,572 people) and nonvertebral fracture by 23% (RR 0.77, 0.68 to 0.87; 5 trials, 6,098 people) versus calcium or placebo, with no significant benefit at 400 IU/day [13]. A separate meta-analysis of 5 trials with 1,237 participants found vitamin D reduced the odds of falling (corrected OR 0.78, 95% CI 0.64 to 0.92) compared with calcium or placebo [14].

Where do higher levels become a problem?

The tolerable upper intake level for adults and teenagers 9 and older, including pregnancy and lactation, is 4,000 IU/day (100 mcg); the IOM describes it as the level above which there is risk of adverse events and not as a target intake [2].

A 25(OH)D above 150 ng/mL (375 nmol/L) is the hallmark of toxicity from overdosing, with symptoms of hypercalcemia: confusion, apathy, recurrent vomiting, abdominal pain, polyuria, polydipsia and dehydration [5]. Toxicity is rare and almost always comes from very large doses of pharmacologic products or from manufacturing and labeling errors [5]. Two documented US cases involved supplements containing more than 1,000 times the labeled daily D3 dose; both patients had severe hypercalcemia, their 25(OH)D took about a year to normalize, and they became normocalcemic and asymptomatic once it fell below 400 ng/mL, without long-term sequelae [15].

Endogenous toxicity is a different route: granulomatous disorders and some lymphomas can cause it by producing the active vitamin D metabolite locally [5]. At the trial doses it reviewed in adults under 50, the 2024 Endocrine Society guideline found no evidence of increased adverse events such as symptomatic hypercalcemia, kidney stones, or kidney disease or failure [16].

Who the 2024 Endocrine Society guideline does suggest vitamin D for

The 2024 recommendations are conditional and apply to people without an established indication for vitamin D or for 25(OH)D testing. The guideline suggests empiric vitamin D for children and adolescents aged 1 to 18 (to prevent nutritional rickets and possibly respiratory infections), adults 75 and older (possibly lower mortality), pregnancy (possibly lower risk of preeclampsia, intrauterine mortality, preterm birth, small-for-gestational-age birth and neonatal mortality), and adults with high-risk prediabetes (to reduce progression to diabetes). It suggests against empiric supplementation above the dietary reference intake in healthy adults younger than 75, and against routine 25(OH)D testing in every population it considered, including people with obesity or dark skin. For adults over 50 who need vitamin D, daily dosing is suggested over intermittent high doses. Optimal doses remain unclear [3].

What else moves the number on your report

Form of vitamin D matters, but less than often claimed. A meta-analysis of randomized trials found D3 raised 25(OH)D more than D2 overall (P=0.001), but the difference came from bolus dosing (P=0.0002) and was lost with daily supplementation [17].

Dietary fat is not required. In a 90-day randomized trial of 62 healthy older adults given a monthly 50,000 IU D3 dose with a high-fat meal, a low-fat meal or no meal, the 12-hour D3 increment was 241 nmol/L with the low-fat meal versus 207 and 201 nmol/L, yet 25(OH)D at 30 and 90 days did not differ between groups [18].

Population context helps with interpretation. In NHANES 2011-2014, covering 16,180 people aged 1 and older, 5.0% were at risk of deficiency (below 30 nmol/L, about 12 ng/mL) and 18.3% at risk of inadequacy (30 to 49 nmol/L, about 12 to 19.6 ng/mL). Risk of deficiency was 17.5% in non-Hispanic Black people versus 2.1% in non-Hispanic white people, peaked at 7.6% among adults 20 to 39, and did not change from 2003 to 2014; supplement users had lower rates [4]. The IOM committee concluded that inadequacy had been overestimated by some groups and called for reassessment of laboratory ranges for 25(OH)D [1].